Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 1996

View Archived Issues

Novel thrombin inhibitors in development at LG Chemical

Heterocyclic tachykinin antagonists revealed by Zeneca

New NK1 antagonists from Ciba-Geigy

Protein tyrosine kinase inhibitors from Warner-Lambert

Anti-TGF-beta MAbs from Celtrix

BMS describes thrombin-activatable plasminogen activator

Japanese researchers describe analgesic tripeptides

Dolastatin 10 derivatives from Teikoku Hormone

Natural antitumor/antifungal agent disclosed by Fujisawa

End-of-the-year European launches for protease inhibitors

U.K. launch for aromatase inhibitor

Bayer launches sustained-release calcium antagonist in U.K.

German launch for bisphosphonate

Thrombolytic agent introduced in Germany

Pharmagenesis forms Chinese joint venture

FDA identifies issues to be addressed for AccuSite approval

U.S. researchers report link between NO formation and AIDS dementia

Geron/P&U collaboration on telomerase inhibitors

Neoprobe files first marketing application with FDA

FDA clears oral monotherapy for PID

Genome Therapeutics and Schering-Plough genomic-based collaboration

Breath-activated inhaler from IVAX licensed to Glaxo Wellcome

Bayer antibacterial cleared for wider use by FDA

Nutropin cleared for marketing

Combination antihypertensive product cleared by FDA

Expanded use of acellular DTP vaccine approved

FDA clears angiotensin II blocker from Ciba

Hyperprolactinemia Rx approved by FDA

Novel anticonvulsant approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...